Wegovy update on Novo Nordisk's capital markets day agenda

According to the program for Novo Nordisk’s capital markets day, one key highlight concerns a Wegovy update. The meeting takes place today, Thursday.

Photo: Stine Tidsvilde

Novo Nordisk’s capital markets day transpires on Thursday, and the pharmaceutical firm has aired some key highlights ahead of the meeting, as announced in a stock notification.

The four main points on the agenda for the day include a focus on how Novo Nordisk can secure growth beyond semaglutide by ”building on core research capabilities and new technology platforms.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs